Zacks Investment ResearchThu, 16 Apr 2026 15:26:05 GMTGlaukos Wins Permanent J-Code for Epioxa Keratoconus TherapyGKOS-0.38%
Zacks Investment ResearchFri, 20 Mar 2026 14:35:34 GMTGlaukos Launches Epioxa, Boosts Growth in Corneal TreatmentsGKOS-0.38%
Zacks Investment ResearchThu, 19 Mar 2026 16:31:21 GMTWhy Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?GKOS-0.38%
Zacks Investment ResearchWed, 18 Feb 2026 16:55:15 GMTGlaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue OutlookGKOS-0.38%
BenzingaWed, 18 Feb 2026 14:34:54 GMTThese Analysts Boost Their Forecasts On Glaukos Following Q4 ResultsGKOS-0.38%
Seeking AlphaWed, 18 Feb 2026 04:14:57 GMTGlaukos Corporation (GKOS) Q4 2025 Earnings Call TranscriptGKOS-0.38%
Zacks Investment ResearchWed, 18 Feb 2026 00:01:32 GMTGlaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to SayGKOS-0.38%
Zacks Investment ResearchTue, 17 Feb 2026 23:25:26 GMTGlaukos (GKOS) Reports Q4 Loss, Beats Revenue EstimatesGKOS-0.38%
Zacks Investment ResearchTue, 10 Feb 2026 16:00:54 GMTGlaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy?GKOS-0.38%
The Motley FoolSat, 31 Jan 2026 21:46:46 GMTDirector Sells GKOS 15,000 Shares for $1.9 MillionGKOS-0.38%
Zacks Investment ResearchThu, 29 Jan 2026 14:36:20 GMTHere's Why You Should Retain Glaukos Stock in Your Portfolio NowGKOS-0.38%
